Skip to content
AnalystLens

Viatris 8-K Report, Financial Results (Nov 6, 2025)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed November 6, 2025
Period End
November 6, 2025
Security
VTRS
In the record · 2020–202610-K1210-Q208-K72

VTRS filed 12 annual reports (10-K), 20 quarterly reports (10-Q) and 72 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Leadership change8-K · Feb ’23Feb ’23
  3. Deal closed8-K · Jul ’24Jul ’24
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed November 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Viatris Inc. reported third quarter 2025 results on November 6, 2025, with total revenues of $3.76 billiona, flat on a reported basis and down 1% on a divestiture-adjusted operational basis, which the company attributes primarily to the negative Indore Impact (approximately $100 million in the quarter).

Adjusted EBITDA was $1.15 billionb, down 10% reported, and adjusted EPS was $0.67, down 11% reported. The company posted a U.S. GAAP net loss of $128.2 million, or $(0.11) per share, driven mainly by a reduction in the fair value of its investment in Biocon Biologics compulsory convertible preferred shares and higher income tax expense. Year-to-date, U.S. GAAP net loss was $3.17 billion, including a $2.9 billion goodwill impairment charge recorded in the first half of 2025.

Viatris raised and narrowed certain 2025 guidance ranges. Total revenues guidance moved to $13.9 billion to $14.3 billionc from $13.5 billion to $14.0 billion, adjusted EBITDA to $4.0 billion to $4.2 billion, and adjusted EPS to $2.25 to $2.35, while free cash flow guidance was lowered to $1.85 billion to $2.15 billion from $1.8 billion to $2.2 billion. The company cited foreign exchange and share repurchases as the primary drivers of the changes.

Year-to-date capital returned to shareholders exceeded $920 milliond, including $500 million in share repurchases, and the company remains on track to return more than $1 billion in 2025. The company also highlighted pipeline and business development progress: it submitted a New Drug Application for a low-dose estrogen weekly patch to the FDA and anticipates approval by mid-2026, completed the acquisition of Aculys Pharma, Inc. (including Japanese rights to pitolisant), and plans to file two JNDAs for pitolisant in Japan in the fourth quarter of 2025. Management also said its enterprise-wide strategic review, launched in February, has identified potential operating efficiencies, and it plans an Investor Event in the first quarter of 2026 to provide a strategic and financial outlook.

02—Key points

Key Highlights

  1. Third quarter 2025 total revenues of $3.76 billion, flat reported and down 1% on a divestiture-adjusted operational basis, impacted by the negative Indore Impact of approximately $100 million.
  2. U.S. GAAP net loss of $128.2 million ($0.11 per share), driven by a reduction in fair value of the Biocon Biologics compulsory convertible preferred shares and higher income tax expense.
  3. Adjusted EBITDA of $1.15 billion (down 10% reported) and adjusted EPS of $0.67 (down 11% reported) for the quarter.
  4. 2025 guidance raised and narrowed: total revenues $13.9–$14.3 billion, adjusted EBITDA $4.0–$4.2 billion, adjusted EPS $2.25–$2.35; free cash flow guidance $1.85–$2.15 billion.
  5. Year-to-date capital returned to shareholders exceeded $920 million, including $500 million in share repurchases; on track for more than $1 billion in 2025.
  6. Low-dose estrogen weekly patch NDA submitted to FDA in late Q3 2025, with approval anticipated by mid-2026.
  7. Completed acquisition of Aculys Pharma, Inc., gaining Japanese rights to pitolisant and Spydia Nasal Spray; two pitolisant JNDAs planned for Q4 2025.
  8. Enterprise-wide strategic review ongoing, with potential multi-year net cost savings; Investor Event planned for Q1 2026.

03—Questions

Frequently Asked Questions

  1. Why did Viatris report a net loss in the third quarter of 2025?

    The U.S. GAAP net loss of $128.2 million was primarily driven by a reduction in the fair value of the company's investment in Biocon Biologics compulsory convertible preferred shares and an increase in income tax expense, according to the filing.

  2. How did Viatris change its 2025 financial guidance?

    Viatris raised and narrowed its guidance ranges: total revenues to $13.9–$14.3 billion (from $13.5–$14.0 billion), adjusted EBITDA to $4.0–$4.2 billion (from $3.89–$4.19 billion), and adjusted EPS to $2.25–$2.35 (from $2.16–$2.30). Free cash flow guidance moved to $1.85–$2.15 billion from $1.8–$2.2 billion. The company attributed the changes primarily to foreign exchange and share repurchases.

  3. What is the Indore Impact?

    The Indore Impact refers to the estimated negative financial effect on 2025 total revenues and earnings from operations versus 2024, caused by supply disruptions and an FDA warning letter and import alert related to the company's oral finished dose manufacturing facility in Indore, India. The estimated impact to total revenues was approximately $100 million in the third quarter and $400 million for the nine months ended September 30, 2025.

  4. What drove the goodwill impairment charge in 2025?

    For the nine months ended September 30, 2025, Viatris recorded a goodwill impairment charge of $2.9 billion, resulting from an interim goodwill impairment test performed as of March 31, 2025.

  5. What are the key upcoming catalysts for Viatris?

    The company expects FDA approval of its low-dose estrogen weekly patch by mid-2026, plans to file two pitolisant JNDAs in Japan in the fourth quarter of 2025, and will hold an Investor Event in the first quarter of 2026 to provide a strategic and financial outlook and details on its enterprise-wide strategic review.

04—Continue

← View all 8-K filings